Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Status:
Completed
Trial end date:
2016-02-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
Determine the likelihood that lenalidomide will adequately control the disease for at least
one year.
Lenalidomide is a drug that alters the immune system and it may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may reduce or prevent the growth of cancer cells. Lenalidomide is approved by the Food and
Drug Administration (FDA) for the treatment of specific types of myelodysplastic syndrome
(MDS) and in combination with dexamethasone for patients with multiple myeloma (MM) who have
received at least 1 prior therapy. MDS and MM are cancers of the blood. It is currently being
tested in a variety of cancer conditions.
In this case it is considered experimental. The lenalidomide being administered in this study
is not a commercially marketed product. Although it is expected to be very similar in safety
and activity to the commercially marketed drug, it is possible that some differences may
exist. Because this is not a commercially marketed drug, lenalidomide can only be
administered to patients enrolled in this clinical trial and may only be administered under
the direction of physicians who are investigators in this clinical trial.